2026-08-26T23:00:29Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1368972026-02-19T09:52:41Zcom_10366_135255com_10366_4512com_10366_3823col_10366_135256

Flores Montero, Juan Alejandro Sanoja Flores, Luzalba Paiva, Bruno Puig Morón, Noemí García Sánchez, Omar Böttcher, Sebastian van der Velden, VHJ Pérez Morán, José Vidriales Vicente, María Belén García Sanz, Ramón Jiménez, C. González Díaz, Marcos Martínez-López, J. Corral-Mateos, A. Grigori, G.E. Fluxá, R. Pontes, R. Caetano, J. Sedek, L. Cañizo Fernández-Roldán, María Consuelo del Bladé, Joan Huerta, Juan José la Aguilar, Carlos Bárez, Abelardo García-Mateo, A. Labrador Gómez, Jorge Leoz, P. Aguilera-Sanz, C. San Miguel, Jesús F Mateos Manteca, María Victoria Durie, Brian van Dongen, Jacques J. M. Orfao de Matos Correia e Vale, José Alberto 2018-02-06T08:06:44Z 2018-02-06T08:06:44Z 2017-10 Leukemia. 2017 Oct;31(10):2094-2103 http://hdl.handle.net/10366/136897 10.1038/leu.2017.29 [EN]Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics. eng https://creativecommons.org/licenses/by-nc-nd/3.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivs 3.0 Unported Oncology Next generation flow Multiple myeloma Minimal residual disease Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma info:eu-repo/semantics/article